Kidney diseases
25 public biotech companies we cover are developing treatments for IgA nephropathy, lupus nephritis, FSGS and other kidney conditions. 11 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Akebia Therapeutics (AKBA)Thesis Intact
Anemia in CKD, IgA nephropathy, Lupus nephritis, Hyperphosphatemia, and 4 more
- ANI Pharmaceuticals (ANIP)Thesis Challenged
Nephrotic syndrome
- Annexon (ANNX)Thesis Intact
Lupus nephritis
- Ardelyx (ARDX)Thesis Challenged
Hyperphosphatemia
- Arrowhead Pharmaceuticals (ARWR)Thesis Intact
Immunoglobulin a nephropathy, Complement mediated renal disease
- Autolus Therapeutics (AUTL)Thesis Intact
Lupus nephritis
- Biohaven (BHVN)Thesis Challenged
IgA nephropathy
- Cabaletta Bio (CABA)Thesis Intact
Lupus nephritis
- Climb Bio (CLYM)Thesis Intact
IgA Nephropathy, Primary Membranous Nephropathy
- Cullinan Therapeutics (CGEM)Thesis Intact
Lupus nephritis
- Eledon Pharmaceuticals (ELDN)Thesis Challenged
Kidney transplantation, Kidney transplant rejection prevention
- InflaRx (IFRX)Thesis Intact
Complement-mediated kidney diseases
- Insight Molecular Diagnostics (IMDX)Thesis Challenged
Kidney transplant rejection
- Ionis Pharmaceuticals (IONS)Thesis Intact
IgA nephropathy
- Jade Biosciences (JBIO)Thesis Intact
IgA nephropathy
- Jasper Therapeutics (JSPR)Thesis Challenged
IgA nephropathy, IGAN, C3G, FSGS, Rare renal disorders, Focal segmental glomerulosclerosis
- Kyverna Therapeutics (KYTX)Thesis Intact
Lupus nephritis
- Nuvectis Pharma (NVCT)Thesis Intact
Lupus nephritis (LN), Immunoglobulin A nephropathy
- Palatin Technologies (PTN)Thesis Challenged
Diabetic nephropathy
- Protalix BioTherapeutics (PLX)Thesis Intact
Rare renal disease
- Silence Therapeutics (SLN)Thesis Intact
Complement-mediated renal diseases
- Talphera (TLPH)Thesis Challenged
Continuous renal replacement therapy
- Tonix Pharmaceuticals (TNXP)Thesis Challenged
Kidney transplant rejection, Kidney transplant rejection prophylaxis
- Travere Therapeutics (TVTX)Thesis Intact
Cystinuria, Immunoglobulin a nephropathy, Primary membranous nephropathy, Focal segmental glomerulosclerosis, and 1 more
- Unicycive Therapeutics (UNCY)Thesis Challenged
Hyperphosphatemia, Acute kidney injury, Delayed graft function, Chronic kidney disease on dialysis
Drug pages
Obecabtagene autoleucel (obe-cel)Mivocabtagene autoleucel (miv-cel)
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Later
- Mar 25in 151 daysOLC · FDA decision · Hyperphosphatemia · chronic kidney disease on dialysis
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in Q4 2026
- Q4 2026Vadadustat · Phase 3b results (VOCAL) · Anemia in CKD · dialysis
- Q4 2026Tegoprubart · Phase 3 start (LEGACY) · Kidney transplant rejection prevention
- Q4 2026JADE101 · Phase 3 start (EVERGREEN) · IgA nephropathy
Expected in H2 2026
- H2 2026BHV-1400 · Phase 3 start · IgA nephropathy
- 2H 2026TNX-1500 · Phase 2 start · Kidney transplant rejection prophylaxis
Expected by end of 2026
- By year-end 2026Vensobafusp alfa · Phase 2 interim results · IgA nephropathy
Expected by end of March 2027
- early 2027CLN-978 · Phase 2a start · Lupus nephritis
Expected in Q2 2027
- Q2 2027JADE101 · Phase 2 interim results (JUNIPER) · IgA nephropathy
- Q2 2027Vensobafusp alfa · Phase 2 interim results · Rare renal disorders · IgAN, C3G, FSGS
Expected in H1 2027
- H1 2027CLYM116 · Phase 2 interim results (NAVIGATE-2) · IgA Nephropathy